BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 31556812)

  • 1. ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure: A Possible Novel Therapeutic Target.
    Omura J; Satoh K; Kikuchi N; Satoh T; Kurosawa R; Nogi M; Ohtsuki T; Al-Mamun ME; Siddique MAH; Yaoita N; Sunamura S; Miyata S; Hoshikawa Y; Okada Y; Shimokawa H
    Circ Res; 2019 Oct; 125(10):884-906. PubMed ID: 31556812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Celastrol as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).
    Kurosawa R; Satoh K; Nakata T; Shindo T; Kikuchi N; Satoh T; Siddique MAH; Omura J; Sunamura S; Nogi M; Takeuchi Y; Miyata S; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1205-1217. PubMed ID: 33472404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
    Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
    Omura J; Habbout K; Shimauchi T; Wu WH; Breuils-Bonnet S; Tremblay E; Martineau S; Nadeau V; Gagnon K; Mazoyer F; Perron J; Potus F; Lin JH; Zafar H; Kiely DG; Lawrie A; Archer SL; Paulin R; Provencher S; Boucherat O; Bonnet S
    Circulation; 2020 Oct; 142(15):1464-1484. PubMed ID: 32698630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension.
    Shults NV; Kanovka SS; Ten Eyck JE; Rybka V; Suzuki YJ
    J Am Heart Assoc; 2019 Mar; 8(5):e011227. PubMed ID: 30807241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension.
    Kurosawa R; Satoh K; Kikuchi N; Kikuchi H; Saigusa D; Al-Mamun ME; Siddique MAH; Omura J; Satoh T; Sunamura S; Nogi M; Numano K; Miyata S; Uruno A; Kano K; Matsumoto Y; Doi T; Aoki J; Oshima Y; Yamamoto M; Shimokawa H
    Circ Res; 2019 Jul; 125(3):309-327. PubMed ID: 31195886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure.
    Park JF; Clark VR; Banerjee S; Hong J; Razee A; Williams T; Fishbein G; Saddic L; Umar S
    Circ Heart Fail; 2021 Feb; 14(2):e007058. PubMed ID: 33541093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane prevents right ventricular injury and reduces pulmonary vascular remodeling in pulmonary arterial hypertension.
    Kang Y; Zhang G; Huang EC; Huang J; Cai J; Cai L; Wang S; Keller BB
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H853-H866. PubMed ID: 32108526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature.
    Dieffenbach PB; Mallarino Haeger C; Rehman R; Corcoran AM; Coronata AMF; Vellarikkal SK; Chrobak I; Waxman AB; Vitali SH; Sholl LM; Padera RF; Lagares D; Polverino F; Owen CA; Fredenburgh LE
    Am J Respir Crit Care Med; 2021 Dec; 204(12):1433-1451. PubMed ID: 34550870
    [No Abstract]   [Full Text] [Related]  

  • 10. FGF12 (Fibroblast Growth Factor 12) Inhibits Vascular Smooth Muscle Cell Remodeling in Pulmonary Arterial Hypertension.
    Yeo Y; Yi ES; Kim JM; Jo EK; Seo S; Kim RI; Kim KL; Sung JH; Park SG; Suh W
    Hypertension; 2020 Dec; 76(6):1778-1786. PubMed ID: 33100045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension.
    Abid S; Marcos E; Parpaleix A; Amsellem V; Breau M; Houssaini A; Vienney N; Lefevre M; Derumeaux G; Evans S; Hubeau C; Delcroix M; Quarck R; Adnot S; Lipskaia L
    Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31320454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.
    da Silva Gonçalves Bós D; Van Der Bruggen CEE; Kurakula K; Sun XQ; Casali KR; Casali AG; Rol N; Szulcek R; Dos Remedios C; Guignabert C; Tu L; Dorfmüller P; Humbert M; Wijnker PJM; Kuster DWD; van der Velden J; Goumans MJ; Bogaard HJ; Vonk-Noordegraaf A; de Man FS; Handoko ML
    Circulation; 2018 Feb; 137(9):910-924. PubMed ID: 29167228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography.
    Inagaki T; Pearson JT; Tsuchimochi H; Schwenke DO; Saito S; Higuchi T; Masaki T; Umetani K; Shirai M; Nakaoka Y
    Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1021-H1036. PubMed ID: 33481696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
    Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
    Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in Mice.
    Omura J; Satoh K; Kikuchi N; Satoh T; Kurosawa R; Nogi M; Otsuki T; Kozu K; Numano K; Suzuki K; Sunamura S; Tatebe S; Aoki T; Sugimura K; Miyata S; Hoshikawa Y; Okada Y; Shimokawa H
    Circ Res; 2016 Jul; 119(2):197-209. PubMed ID: 27217398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.
    Calvier L; Boucher P; Herz J; Hansmann G
    Circ Res; 2019 Jun; 124(12):1778-1785. PubMed ID: 31023188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
    Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S
    Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension.
    Potus F; Ruffenach G; Dahou A; Thebault C; Breuils-Bonnet S; Tremblay È; Nadeau V; Paradis R; Graydon C; Wong R; Johnson I; Paulin R; Lajoie AC; Perron J; Charbonneau E; Joubert P; Pibarot P; Michelakis ED; Provencher S; Bonnet S
    Circulation; 2015 Sep; 132(10):932-43. PubMed ID: 26162916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
    Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
    Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice.
    Li H; Li X; Hao Y; Wu C; Fu Y; Su N; Chen H; Ying B; Wang H; Su L; Cai H; He Q; Cai M; Sun J; Lin J; Scott A; Smith F; Huang X; Jin S
    Br J Pharmacol; 2022 Nov; 179(22):5132-5147. PubMed ID: 35764296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.